This is Mr. Shah’s story.
How to sell a pharmacy at the right time, to the right buyer, for the right price is the question Vikram Shah, PharmD had been carrying for almost a year before he finally picked up the phone. When the right time came, he called CGK Business Sales. Vikram ran a $4.2M revenue, $850K SDE independent pharmacy out of a University Boulevard storefront near the Round Rock Premium Outlets corridor in the Austin metro, Texas. Eighteen W-2 employees moved through the floor each week: Vikram plus three staff PharmDs, eight pharmacy technicians, four delivery drivers, and two admin and billing staff. The business ran 55 percent on retail prescription dispensing for Round Rock, Cedar Park, Pflugerville, and Hutto families across Tricare and major commercial insurance, 25 percent on route-based same-day home delivery to roughly 280 chronic-medication patients, 15 percent on sterile and non-sterile compounding for veterinary, hormone replacement, pediatric flavoring, and dermatology, and the remaining 5 percent on durable medical equipment and supplemental retail. Approximately 12,400 active patient households across the north Austin suburbs were on the dispensing roster, plus 14 long-term care facility contracts where Vikram’s pharmacy provided bubble-pack medication management for 280-plus residents combined. Vikram was 58. He had founded the pharmacy in 1999 right out of UT Austin’s College of Pharmacy, and over twenty-six years he had grown it into an 18-person independent pharmacy with USP 797 sterile compounding and USP 800 hazardous-drug compounding certifications (rare for an independent pharmacy, only about 7 percent of US independents hold both certs), a 4.8-star Google rating across 620-plus reviews, and an 87 percent medication-therapy-management completion rate against an industry average of 60 to 70 percent. His older daughter Priya was a hospital pharmacist at Houston Methodist, his son Arjun was a software engineer at a SaaS company in Austin, and his wife Meera (a Round Rock ISD elementary school teacher) had been telling him for two years it was time to slow down. He came to us in mid-2025 because he did not know who else to talk to about how to sell a pharmacy at this size, with USP 797 and USP 800 certifications, a meaningful LTC bubble-pack book, in-network status across Tricare and the major commercial insurers, and three staff PharmDs in their late thirties and early forties who were ready to keep running the operation post-close. This page is what happened next, and what could happen for you. Vikram is a composite, not a single real CGK seller, but the patterns and details are pulled from real independent pharmacy engagements.
The night before Vikram decided to sell a pharmacy.
Most owners who decide to sell a pharmacy have been carrying the question quietly for a year or more before they reach for the phone. Vikram was no different. He was 58. For twenty-six years he had been the pharmacist of record on every controlled-substance log at the Round Rock counter, the founder who had personally signed the lease in 1999 on a 2,800 square foot storefront on University Boulevard, the lead consultant on every USP 797 and USP 800 sterile-compounding workflow audit the pharmacy ever sat through, the relationship lead on each of the 14 long-term care facility contracts the pharmacy held, and the after-hours phone line for roughly 280 chronic-medication delivery patients who could call him personally if a refill ran late on a Sunday night. The pharmacy did $4.2 million in annual revenue, $850,000 in Seller’s Discretionary Earnings at the upper end of independent-pharmacy norms (driven by the compounding and LTC mix), and eighteen W-2 employees including three staff PharmDs (Aisha Patel, age 38; Daniel Ruiz, age 41; and Jenna Okafor, age 44), eight pharmacy technicians, four delivery drivers running the same-day route across Round Rock, Cedar Park, Pflugerville, and Hutto, and two admin and billing staff. The pharmacy served roughly 12,400 active patient households across the north Austin suburbs and 14 long-term care facility contracts where it provided bubble-pack medication management for 280-plus seniors combined. The compounding practice served 6 veterinary clinics, 4 OB/GYN practices, 2 endocrinology practices, and 8 dermatologists across the Austin metro. Vikram held USP 797 sterile compounding certification and USP 800 hazardous-drug compounding certification (rare for an independent pharmacy), the pharmacy ran on the PrimeRx pharmacy management system Vikram had migrated to in 2014, and the operation was in-network with Tricare, BlueCross BlueShield TX, UnitedHealthcare, Aetna, Cigna, Humana, and Medicare Part D and Texas Medicaid.
Why owners decide to sell a pharmacy
The Friday Vikram finally submitted the form, his wife Meera had been at his shoulder reading him the printed search results from her phone. Meera was a Round Rock ISD elementary school teacher, a Gujarati immigrant who had come to the United States with Vikram in 1991 when he was finishing pharmacy school at UT, and she had been the one keeping the house running for twenty-six years while Vikram was at the pharmacy six days a week. Their older daughter Priya had launched and was working as a hospital pharmacist at Houston Methodist. Their son Arjun had launched and was working as a software engineer at a SaaS company in Austin. Neither was coming home to take over the pharmacy. Vikram was on the board of the Round Rock Hindu Temple, and he wanted to expand the pro-bono medication-counseling work he had been doing on Saturdays for first-generation South Asian immigrant families who could not navigate the Medicare Part D plan finder on their own. He wanted to be in his temple work, in his counseling work, and at home with Meera. The three staff PharmDs were 38 to 44 years old and had each been with the pharmacy for at least seven years. Aisha Patel had been there nine years and ran the compounding lab. Daniel Ruiz had been there eight years and ran the LTC bubble-pack workflow. Jenna Okafor had been there seven years and ran the retail counter and the MTM consultations. All three were committed to staying on post-close if the buyer ran the business as an independent pharmacy rather than absorbing it into a corporate brand. Vikram had been approached eleven times in the prior eighteen months: four times by PE-backed independent pharmacy consolidators headquartered out of Tennessee, Ohio, and Florida, three times by a regional independent pharmacy chain based in Houston that was expanding its Central Texas footprint, twice by national chain pharmacy buyer reps (one from a national drugstore chain and one from a national grocery pharmacy chain), and twice by individual pharmacist buyers in their early forties trying to put together SBA-financed acquisitions. Vikram did not know what his pharmacy was actually worth at $4.2 million revenue and $850,000 SDE, with the USP 797 and USP 800 certifications, the LTC contracts, the 4.8-star Google rating, and the 87 percent MTM completion rate. He did not know whether the firms calling him were the right buyers for his three staff PharmDs, his eight pharmacy technicians, his four delivery drivers, or his two admin and billing staff. He did not know whether the LTC bubble-pack book or the compounding mix was a value driver or a buyer-friction point. He did not have a single peer in his life who had ever sold an independent pharmacy at this size and certification depth.
That is the night he found CGK and submitted the form. We called him back at 8:14 the next morning, while Vikram was at the Round Rock counter between the morning controlled-substance log review and the first delivery-route dispatch.
The first call about how to sell a pharmacy.
The first call was 47 minutes. We did most of the listening.
Owners who think about how to sell a pharmacy in their late fifties, like Vikram, usually carry the same handful of pressures into the first call. Vikram talked about his three staff PharmDs and the way each one carried a different operating book. Aisha Patel ran the USP 797 and USP 800 compounding lab and had been the practical lead on the 6 veterinary clinic, 4 OB/GYN, 2 endocrinology, and 8 dermatology relationships the compounding practice served. Daniel Ruiz ran the LTC bubble-pack workflow and had been the relationship lead on most of the 14 long-term care facility contracts. Jenna Okafor ran the retail counter, the medication-therapy-management consultations, and the chronic-disease counseling work that had landed Vikram his 87 percent MTM completion rate. He talked about his eight pharmacy technicians, three of whom had been with him for more than a decade and had been the practical operators of the same-day delivery route. He talked about the 14 long-term care facility contracts and the bubble-pack workflow he had personally designed in 2008, which had eventually become the operational backbone of the LTC pipeline. He talked about the compounding lab and the USP 797 and USP 800 certifications it had taken him twelve years and three rounds of buildouts to land. He talked about the in-network insurance contracts with Tricare, BlueCross BlueShield TX, UnitedHealthcare, Aetna, Cigna, Humana, Medicare Part D, and Texas Medicaid, and the way each of those network credentialing files needed individual transfer attention at close. He talked about the PrimeRx pharmacy management system he had migrated to from a legacy system in 2014. He talked about the Round Rock Hindu Temple community network that had driven his first 200 patients in 1999 to 2002 and the way the temple work was something he wanted to actually go do once the operating-day pressure was off him. He talked about Meera and the way she had been the steady voice telling him to slow down for two years. We asked about the pharmacy the way you would ask if you were trying to understand it, not the way you would ask if you were trying to win the engagement. What we were listening for was not just the financials. We were listening for whether Vikram was actually ready to sell, what he was working toward, and whether his expectations on price were grounded in what the independent pharmacy M&A market would actually support.
At the end of that call, we set up a working session: an in-person conversation where one of our Managing Directors would walk Vikram through our valuation model and tell him honestly what his pharmacy was likely to command. We did not promise him a written report. Written valuations involve substantially more work, and we charge for those when a seller actually needs one for partnership buyout, estate planning, a divorce, or another documentary purpose. The walkthrough was free because Vikram was clearly thinking seriously about how to sell a pharmacy, the way someone thinks about it before they actually do it. Whether that ends up being in a year, five years, or longer, we make the same call.
The valuation session was the following Wednesday at 7:15 a.m. at the Round Rock pharmacy, before the 8:00 a.m. counter open and after Vikram had finished his morning USP 797 lab cleanroom verification with Aisha Patel.
Vikram was not ready to sell a pharmacy yet. He went home and waited three months.
The valuation session showed Vikram that his pharmacy was worth meaningfully more than he had been hoping in some areas and meaningfully less in others, which is how these conversations usually go. The USP 797 and USP 800 sterile-compounding certifications, the 14 long-term care facility contracts (a recurring-revenue book a sophisticated buyer treats almost like an institutional contract roster), the 4.8-star Google rating across 620-plus reviews, the 87 percent MTM completion rate, and the 26-year operating history under a single founder were all premium-multiple drivers a sophisticated independent pharmacy chain or PE-backed consolidator would pay up for. Three issues, though, were dragging the number down. The first was the network credentialing transfer story. Tricare, BlueCross BlueShield TX, UnitedHealthcare, Aetna, Cigna, Humana, Medicare Part D, and Texas Medicaid each had its own contract-transfer mechanics that required separate underwriting on the buyer’s side, and Vikram had not yet pulled his credentialing files into a single buyer-grade folder. The second was the LTC contract documentation. Several of the 14 long-term care facility relationships had been operating on handshake-extended evergreen terms with informal renewal language rather than formally signed multi-year contracts, which a sophisticated buyer’s diligence team was going to underwrite as a transition-risk factor on a recurring-revenue book worth roughly 20 percent of the pharmacy’s gross. The third was the pharmacist-of-record continuity story. Vikram was personally listed as pharmacist-in-charge on the Texas State Board of Pharmacy license, and the buyer’s diligence team was going to need a clean transition to one of the three staff PharmDs (most likely Daniel Ruiz given his LTC operational depth) along with a documented stay arrangement.
We told Vikram honestly: he could go to market now and accept the discount, or he could spend three months pulling the network credentialing files into a single transfer-ready folder for each of the eight insurance networks, formalizing multi-year contracts on each of the 14 long-term care facility relationships (or where the LTC partner would not sign a multi-year, at minimum a one-year commitment with a transferability clause that survived a change of control), and structuring a documented pharmacist-in-charge transition plan that named Daniel Ruiz as the post-close PIC with a three-year stay arrangement. We said the second path would likely command a meaningfully better number from a wider range of buyers, especially a regional independent pharmacy chain with a satellite-brand preservation thesis or a PE-backed consolidator with an underwriter that cared about LTC contract documentation. The realistic buyer pool for a $4.2 million revenue, $850,000 SDE, USP 797 and USP 800-certified independent pharmacy with an LTC book and a compounding mix is wider than people think, but each band of buyer prices the same pharmacy differently, and the cleaner the diligence file is the more buyers can compete. CGK is an active member of the International Business Brokers Association and the M&A Source, both of which give us deep visibility into the active independent pharmacy buyer landscape, and we are in regular dialogue with the National Community Pharmacists Association on independent pharmacy M&A trends.
This is the part most brokers skip. Most brokers would have signed Vikram that day, taken him to market, and made the commission whether or not the deal was the best one for him. We told him to wait, even though it meant we did not get paid for three months and might never get paid at all if he changed his mind.
Vikram went home and waited. He spent the next three months pulling each of the eight insurance network credentialing files into transfer-ready folders, walking each of the 14 long-term care facility administrators through a formal multi-year or one-year-with-change-of-control contract conversation (twelve of the fourteen signed multi-year terms, two signed one-year-with-change-of-control language), structuring a documented pharmacist-in-charge transition plan that named Daniel Ruiz as the post-close PIC with a formal three-year stay arrangement, and tightening the USP 797 and USP 800 cleanroom audit documentation into a buyer-grade compliance binder. He read background material on independent pharmacy M&A through the American Pharmacists Association and stayed close to NCPA’s independent pharmacy ownership-transition resources while watching pharmacy chain acquisition announcements in the trade press. He called us back in late 2025 and said he was ready to sell a pharmacy that was finally in the shape it needed to be in.
What we did when Vikram came back.
What it takes to sell a pharmacy properly
When an owner is ready to sell a pharmacy with CGK, the speed of the on-ramp surprises them. We took Vikram’s pharmacy to market in just over five weeks once he got us his updated financials, the eight insurance network credentialing transfer-ready folders, the formalized 14 long-term care facility contracts, the documented pharmacist-in-charge transition plan with Daniel Ruiz as the named successor PIC, the USP 797 and USP 800 cleanroom compliance binder, the three-year stay arrangements he had pre-negotiated with Aisha Patel, Daniel Ruiz, and Jenna Okafor, the sub-segment-by-sub-segment revenue and margin breakouts (retail dispensing, home delivery, sterile and non-sterile compounding, durable medical equipment), the script-by-script mix data pulled out of PrimeRx for the trailing thirty-six months, the patient-household-by-patient-household revenue concentration map for the top thirty LTC and chronic-delivery accounts, the Texas State Board of Pharmacy license documentation, the Drug Enforcement Administration controlled-substance registration history, the lease terms on the University Boulevard storefront, and the full P&L breakouts across all four sub-segments. The blind teaser went out to thirty-one buyers we had pre-qualified, a tighter funnel than other industries because the independent pharmacy M&A buyer pool is structurally concentrated. Buyers fell across four buckets we routinely use to think about how to sell a pharmacy: PE-backed independent pharmacy consolidators (active across Tennessee, Ohio, Florida, and a few national platforms, typically running multi-state roll-up theses with central wholesaler contracting and IT consolidation), regional independent pharmacy chains (privately held, often family-owned, expanding their state or multi-state footprint through targeted acquisitions and typically operating acquired pharmacies under their original brand names), national chain pharmacy buyer programs (the smallest band by deal volume but historically active on stronger-margin independents, typically absorbing brand and rebranding within ninety days), and individual pharmacist buyers running SBA-financed or seller-note-financed acquisitions (the most active buyer pool by count but the smallest by check size, typically focused on retail-heavy pharmacies under $3 million revenue). Each bucket prices the same pharmacy differently.
Twenty-three of the thirty-one buyers signed NDAs and received the full Confidential Information Memorandum. Thirteen submitted Indications of Interest after data-room review. Seven advanced to Letters of Intent. We narrowed to four for management presentations. Two re-submitted refined LOIs after the management meetings. Both went into a final-final negotiation cycle.
Vikram decided between two of the top LOIs. They were materially different. One was a slightly higher headline price from a PE-backed independent pharmacy consolidator headquartered in Tennessee with a multi-state roll-up thesis, where the Round Rock pharmacy would absorb into the consolidator’s central wholesaler contracting and IT stack within ninety days, the local brand name would close at acquisition (the consolidator operated all acquired pharmacies under a single national identity), Vikram would transition to a one-year strategic-advisor role with no continuing patient-facing involvement, the three staff PharmDs would absorb under the consolidator’s standardized PharmD comp model (which sat below the comp model Vikram had built), and the eight pharmacy technicians would absorb under a different scheduling system that would meaningfully reduce overtime hours for at least four of the eight techs. The other was a slightly lower headline price from a Texas-based regional independent pharmacy chain headquartered in Houston with around 38 locations across Texas, Oklahoma, and Louisiana, roughly $180 million in annual revenue, and a long-hold thesis (the chain was privately held by an extended Texas-Oklahoma pharmacist family, not PE-backed). Under that LOI, Vikram’s pharmacy would keep its existing brand name on the storefront (the chain operates each acquired pharmacy under its original brand with central wholesaler contracting, insurance credentialing support, IT support, and back-office accounting consolidated up to the parent), the eighteen-person bench would stay in the University Boulevard location, the three staff PharmDs would absorb at or above their existing comp under the chain’s PharmD compensation framework with Daniel Ruiz formally named as the post-close pharmacist-in-charge, the eight pharmacy technicians, four delivery drivers, and two admin and billing staff would retain their roles and pay structure, the USP 797 and USP 800 sterile-compounding lab would continue operating as the chain’s Central Texas compounding hub serving multiple chain locations, the 14 LTC contracts would transfer cleanly under the chain’s master LTC services umbrella, the in-network insurance contracts with Tricare, BlueCross BlueShield TX, UnitedHealthcare, Aetna, Cigna, Humana, Medicare Part D, and Texas Medicaid would transfer through the chain’s central credentialing team, Vikram would step back to a two-year transition consulting role at one day per week with full freedom to spend the rest of his time on his Round Rock Hindu Temple work, and the chain committed to retaining the existing PrimeRx system for the Round Rock pharmacy through a 24-month integration window. We walked Vikram through what each LOI would actually deliver under realistic and pessimistic scenarios, including what the cultural continuity would look like for his three staff PharmDs, his eight pharmacy technicians, his four delivery drivers, and his two admin and billing staff under each acquisition structure. The Texas-based regional chain deal was the better one for Vikram. The two-year consulting role gave him the structural off-ramp he needed to fully step into his temple work and his community medication-counseling work. The bench preservation kept his three staff PharmDs and the broader eighteen-person team in the roles they had earned. The local brand preservation kept the Round Rock storefront the storefront the patient households recognized.
Through the whole process, the same CGK Managing Director who had taken Vikram’s first call three months earlier was the person walking him through every conversation.
The deal Vikram took to sell a pharmacy.
How the deal looks when you sell a pharmacy with CGK
This is the part of how to sell a pharmacy that gets the least attention in the trade press and the most attention from owners who have actually closed a transaction: the structure of the consideration package matters more than the headline number, and the structure for an independent pharmacy with USP 797 and USP 800 certifications, an LTC contract book, and an in-network insurance roster is meaningfully different from the structure typical of every other industry CGK works in. Vikram’s deal closed roughly seven months after we restarted the engagement, the longer end of the typical CGK retail and healthcare-services window because pharmacy M&A involves Texas State Board of Pharmacy license transfer mechanics, DEA controlled-substance registration transfer, eight separate insurance network credentialing transfer files, fourteen LTC contract change-of-control notifications, USP 797 and USP 800 compounding facility re-inspection, and a more involved pre-close due diligence cycle on the controlled-substance log and the PrimeRx data migration than typical industry M&A. The buyer was the Texas-based regional independent pharmacy chain headquartered in Houston with thirty-eight locations across Texas, Oklahoma, and Louisiana, roughly $180 million in annual revenue, privately held by an extended Texas-Oklahoma pharmacist family with a long-hold thesis, and a structured Central Texas expansion strategy that had absorbed three prior independent pharmacies in Austin, San Antonio, and Waco in the prior twenty-four months. The acquisition structure was an asset purchase rather than a stock purchase: the pharmacy folded into the chain at close while keeping its existing storefront brand name, the eighteen-person bench stayed at the University Boulevard location, the three staff PharmDs absorbed at or above their existing comp with Daniel Ruiz formally named as the post-close pharmacist-in-charge, the eight pharmacy technicians, four delivery drivers, and two admin and billing staff retained their roles and pay structure, the USP 797 and USP 800 sterile-compounding lab continued operating as the chain’s Central Texas compounding hub serving multiple chain locations, the 14 LTC contracts transferred cleanly under the chain’s master LTC services umbrella, and Vikram transitioned to a two-year consulting role at one day per week.
The total deal economic value was approximately $5.1 million, roughly 6 times trailing SDE, a premium independent pharmacy multiple driven by the USP 797 and USP 800 sterile-compounding certifications, the LTC contract book, the 4.8-star Google rating, the 87 percent MTM completion rate, the 26-year operating history under a single founder, the diversified sub-segment mix (retail, delivery, compounding, DME), and the structured succession story Vikram had built during the wait period. About 80 percent of it came as cash at closing, a higher percentage than industries like law firms (where attorney-client retention drives a longer escrow). About 8 percent was held back in escrow for 12 months, a standard pharmacy escrow window because patient-household retention through a chain transition with brand preservation is verified within twelve months, and because the LTC contract change-of-control consents can be reasonably underwritten on a one-year horizon. The remaining 12 percent was a rollover-as-equity stake into the chain’s holding company, with Vikram’s existing equity converting into the chain’s holding-company partnership interests on a vesting schedule tied to his continued two-year consulting involvement. The rollover percentage runs lower in independent pharmacy deals than in many other industries because pharmacy chain buyers running long-hold theses generally prefer cash-heavy structures with shorter consulting windows. The numbers add up to one hundred. Wire hit on a Friday morning at 9:47 a.m. while Vikram was at the Round Rock pharmacy.
Vikram stayed on as a transition consultant for the chain’s Central Texas region for twenty-four months after closing, dropping to one day per week so he could personally introduce each of the 14 LTC facility administrators to Daniel Ruiz as the new pharmacist-in-charge, walk Aisha Patel through the chain’s central wholesaler contracting on the compounding ingredient supply, accompany Jenna Okafor on the chain’s MTM workflow integration meetings, and shape the chain’s Central Texas compounding-hub strategy across the three other Austin-metro chain pharmacies that began routing their compounding scripts to the Round Rock lab post-close. After twenty-four months, Vikram stepped back to a quarterly clinical-advisor relationship that gave him room to spend the bulk of his weeks on his Round Rock Hindu Temple board work and on the pro-bono medication-counseling clinic he had been thinking about for two years.
What happened to Vikram’s people and his patients.
The people-side of how to sell a pharmacy usually weighs heavier on the founding pharmacist than the financial-side, even when the financial-side is what triggers the call to a broker in the first place. Vikram cared most about his three staff PharmDs (Aisha Patel, Daniel Ruiz, and Jenna Okafor), the eight pharmacy technicians (three of whom had been with him for more than a decade), the four delivery drivers running the same-day route across Round Rock, Cedar Park, Pflugerville, and Hutto, the two admin and billing staff who had run the day-to-day operations of the storefront since the pharmacy moved into the University Boulevard space in 2007, and the active patient roster: about 12,400 active households across the north Austin suburbs, the 280-plus chronic-delivery patients, the 280-plus LTC residents being served through the bubble-pack workflow, and the compounding patients across the 6 veterinary clinic, 4 OB/GYN, 2 endocrinology, and 8 dermatology relationships. The Texas-based regional chain buyer was a privately held long-hold operator that intended to actually preserve the Round Rock pharmacy as a standing local-brand storefront under its original name rather than absorb it into a national identity on a tight ninety-day timeline. That made the people part substantially cleaner than it would have been under the higher-headline-price PE-backed consolidator deal that wanted to absorb the pharmacy into the consolidator’s national brand and rebrand within ninety days.
The buyer kept all eighteen W-2 employees, honored the existing pay structure across PharmDs, technicians, drivers, and admin staff, and committed to keeping Aisha Patel running the USP 797 and USP 800 compounding lab as the new Central Texas compounding hub, Daniel Ruiz running the LTC bubble-pack workflow as the formally named post-close pharmacist-in-charge, and Jenna Okafor running the retail counter and the MTM consultations. The pharmacist-of-record continuity work Vikram had done during the wait period (formalizing the Daniel Ruiz pharmacist-in-charge succession and pre-negotiating three-year stay arrangements with each of the three staff PharmDs) was preserved with formal employment agreements at or above the existing comp model. The eight pharmacy technicians retained their roles and existing scheduling structure, including the overtime-eligible same-day delivery dispatch role on Saturdays. The four delivery drivers retained their same-day routes across Round Rock, Cedar Park, Pflugerville, and Hutto. The two admin and billing staff retained their roles and pay. The USP 797 and USP 800 cleanroom certifications transferred cleanly through the chain’s central compliance team. The PrimeRx pharmacy management system was retained for the Round Rock pharmacy through a 24-month integration window before any consolidation onto the chain’s enterprise stack. The 14 LTC contracts transferred under the chain’s master LTC services umbrella with twelve of the fourteen signing multi-year language and the other two extending one-year-with-change-of-control terms. The eight in-network insurance contracts (Tricare, BlueCross BlueShield TX, UnitedHealthcare, Aetna, Cigna, Humana, Medicare Part D, and Texas Medicaid) transferred through the chain’s central credentialing team. The Texas State Board of Pharmacy license transferred through a structured PIC change-of-record window. The DEA controlled-substance registration transferred cleanly. The Round Rock Hindu Temple community network and the 4.8-star Google rating across 620-plus reviews stayed firmly attached to the storefront because the brand and the storefront and the people stayed in place.
Vikram was at the Round Rock pharmacy on a Friday morning when the wire confirmation came through. Pharmacy closings often happen at the end of the week to coincide with weekend script-volume cycles. He walked across the dispensing counter to his counseling room, where he was about to meet with a 78-year-old Type 2 diabetic patient he had been counseling for nineteen years on insulin titration. He took the consultation first. The patient, who did not know what had just happened, walked out half an hour later with a refilled glargine pen and a new plan for the next ninety days. Vikram closed the counseling-room door, drove home to the family house in Cedar Park where Meera was preparing dinner, walked into the kitchen, and said in Gujarati: “Pura thayu.” It is complete. Meera did not say anything. She kissed his forehead. She stood at the stove for thirty seconds without moving. Then she asked what he wanted for dinner.
What Vikram told us afterward.
Why owners who sell a pharmacy with CGK keep coming back
Most owners who sell a pharmacy do not call the broker again in the first year. The ones who do call usually want to talk about the parts of the engagement that, in retrospect, mattered more than they realized at the time. About six months after closing, Vikram called the Managing Director who had run his engagement. He said two things that the Managing Director still tells new sellers about.
The first was about the three-month wait. He said: “Three of the buyers who had been calling me were ready to sign LOIs in thirty days, and two different pharmacy consultants I talked to before you told me they could take me to market right then with the network credentialing files still scattered across eight folders and the LTC contracts still on handshake-evergreen terms. The reason I sold with you is that you told me the truth about how my USP 797 and USP 800 certifications and my LTC book were actually being valued by a sophisticated regional pharmacy chain underwriter, the truth about what the change-of-control LTC contract conversion would buy me in LOI conversations five months later, and the truth about what the formalized Daniel Ruiz pharmacist-in-charge succession would buy me in management-presentation conversations. You told me what would happen to the price if I went out without fixing those things. I would have left more than half a million dollars on the table, and Aisha and Daniel and Jenna would have folded into a worse comp tier under a different operator.”
The second was about who he sold to. He said: “I almost signed with the higher-headline-price PE-backed consolidator because the number on the top line was bigger and they told me they could close in sixty days. The fact that you walked me through what each buyer would actually do with my three staff PharmDs, my eight pharmacy technicians, the storefront I had run for twenty-six years, and the LTC relationships I had built over twenty years, what each buyer’s brand-and-bench integration thesis would mean for the patient households three and five years out, and how a Texas-based regional chain with a satellite-brand preservation thesis was structurally different from a PE-backed consolidator with a single-brand absorption thesis, is a conversation I never even thought to have until you raised it. I sold to a buyer who is actually going to keep the Round Rock storefront the storefront my patients walk into and recognize.”
This is what we mean when we say we sit with you in the decision, not just the transaction. Vikram is one composite story, but the pattern is real. The owners we work with who decide to sell a pharmacy usually find their way to us through versions of Vikram’s situation, and the relationships start with a long listening session and a free walkthrough, not a pitch.
Ready to sell a pharmacy? Where are you in Vikram’s story?
If you are starting to think about how to sell a pharmacy, we should talk. There is no commitment and no pressure. The first conversation is free. The valuation walkthrough that follows is free when you are seriously thinking about selling, whether that is in a year, five years, or longer. We only charge for formal written valuations, and only when you actually need one for a partnership buyout, estate planning, or another documentary purpose. Submit the form and a senior CGK Managing Director will reach out within one business day.
If you are Vikram at month 1: just exploring
You are not sure if you want to sell yet. The independent pharmacy M&A landscape keeps shifting, your insurance network credentialing files are scattered across eight separate folders, your LTC contracts are running on handshake-evergreen terms, your pharmacist-in-charge succession plan is still informal, your USP 797 or USP 800 cleanroom audit binder is incomplete, twenty-plus years of running the counter is starting to tell you something, your kids are not coming back to the pharmacy, you are curious about how a buyer would value your retail dispensing exposure versus your compounding mix or your LTC bubble-pack book, or maybe a PE-backed consolidator or a regional pharmacy chain has been calling you. Most of our best engagements start here. Submit the form and we will schedule a working session. You walk away with a real number and a clear sense of what to do next, with no obligation to do anything.
If you are Vikram at month 3: ready to go
You have done the work to clean up the pharmacy. The financials are tight. Your insurance network credentialing files are pulled into transfer-ready folders for each network. Your LTC contracts are formalized with multi-year terms or one-year-with-change-of-control language. Your pharmacist-in-charge succession plan names a specific staff PharmD and includes a formal stay arrangement. Your USP 797 and USP 800 cleanroom audit documentation is in a buyer-grade compliance binder. Your script-by-script mix from PrimeRx is pulled into a buyer-grade report. Your Texas State Board of Pharmacy license documentation is current. Your DEA controlled-substance registration history is documented. Maybe a buyer is already in the conversation. You want to run a real process. Submit the form and we will be in touch within a business day to talk about timing, scope, and what your first 30 days as a CGK seller would look like.
If you are not sure where you are
Most owners are not sure. Submit the form and start with the conversation. We will figure out together where you are. We are equally happy to tell you to wait twelve months as we are to take you to market in five weeks.
Or call us directly at (888) 858-7191.
Start your own story
A senior CGK Managing Director will respond within one business day. Strictly confidential. For owners of independent pharmacies doing $1.5M+ in annual revenue, including retail community pharmacies, sterile and non-sterile compounding pharmacies, long-term care and assisted-living pharmacy operators, specialty pharmacies, home-delivery pharmacies, and durable medical equipment retailers. The first conversation and the valuation walkthrough that follows are free for any seller seriously thinking about selling, on any horizon.
Confidential. No obligation. Direct routing to a named CGK business broker, not a junior screener.
One of these eight people would lead your engagement.
When you decide to sell a pharmacy with CGK, one named senior Managing Director stays with you from the first call through the wire transfer, just like Vikram’s Managing Director stayed with him for three months and then for the engagement that followed. Our Managing Directors come from Wall Street investment banks, hedge funds, Fortune 500 corporate finance, and operating-business leadership. Cornell MBA. U Chicago Booth MBA. CFA. CMT. Naval Academy. Goldman Sachs. Merrill Lynch. Deutsche Bank. AIG. T. Rowe Price.
What sellers say after they sell a pharmacy (and other businesses) with CGK
I could not be happier with the experience I had selling my business with CGK. Greg did a detailed analysis of my business and helped me price and position it right for the market. After receiving multiple offers at full asking price, the rest of the process went very smoothly, and we closed in less than two months.
Hanna M.Selling my business was a once-in-a-lifetime experience, and I’m incredibly grateful to have had Wes by my side throughout the process. He brought perspective, pushed when necessary, and always had my best interests in mind. His experience and strategic approach allowed me to maximize the sale price while minimizing long-term risk and obligations. If I had to do it all over again, I wouldn’t hesitate to choose him as my broker.
Adam NevilleDerik located multiple interested strategic buyers that produced more than one serious offer. The negotiations were tough but Greg and Derik’s experience helped us overcome. We got a great result for our employees and for the owners. We would recommend them without reservation.
Bob TaylorWe sold a business that was 47 years old and being run by second generation within a year of working with Wes. CGK has a system that attracts serious prospects to review opportunities. Wes was able to make the overwhelming feeling of selling easy and to a certain extent enjoyable. I never felt alone or in the dark throughout the entire process.
Jennifer WilliamsWe decided to sell our company in 2025. Talked to another M&A company in the Houston area. We felt very comfortable with Greg and Matthew at CGK. Could not have made a better choice. From day 1 till final closing and even after 30+ days, they have been here helping us with documents and support during the transition. Thanks can not be said enough.
Rickey ThomasInside the Blueprint, on Bloomberg TV and Fox Business News.
Vikram’s son Arjun, the SaaS-company software engineer in Austin, was the one who first sent him a clip of CGK on Bloomberg. He had been watching the segment in his apartment on a Sunday morning and recognized the firm name from a community pharmacy trade article about how to sell a pharmacy he had read a few months earlier. He texted his father the link with a note that read “Dad, watch this. This looks like the right firm for the conversation you and Mom keep having.” CGK Business Sales is featured on Inside the Blueprint, the syndicated business television series. Our episode aired on Bloomberg TV and Fox Business News. Watch the segment, then start a confidential conversation.
The CGK office Vikram called was the CGK Austin office. Yours might be one of these.
When you sell a pharmacy with CGK, whichever office you reach, you get the entire firm. Vikram worked with a CGK Managing Director based out of the firm’s Austin office, but his deal benefited from a buyer pool we sourced firm-wide, including the Texas-based regional independent pharmacy chain headquartered in Houston that ultimately won the engagement. Click any city to learn about our local presence and the named Managing Director leading that market.
Other Questions Vikram and Other Pharmacy Sellers Ask Us
Practical answers to what comes up before, during, and after the kind of engagement Vikram went through, when you sell a pharmacy with CGK.